Xenon Pharmaceuticals Inc. (XENE) SVP Acquires $24,800.00 in Stock
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) SVP James R. Empfield purchased 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 15th. The shares were acquired at an average price of $2.48 per share, for a total transaction of $24,800.00. Following the completion of the purchase, the senior vice president now directly owns 10,000 shares in the company, valued at approximately $24,800. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Shares of Xenon Pharmaceuticals Inc. (NASDAQ XENE) traded up 5.36% during mid-day trading on Friday, hitting $2.95. 66,700 shares of the company were exchanged. The company has a 50 day moving average of $3.12 and a 200 day moving average of $4.89. The company’s market capitalization is $53.09 million. Xenon Pharmaceuticals Inc. has a 52 week low of $2.25 and a 52 week high of $9.95.
Xenon Pharmaceuticals (NASDAQ:XENE) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.38) by $0.03. The firm had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.38 million. Xenon Pharmaceuticals had a negative return on equity of 47.53% and a negative net margin of 3,489.63%. Equities analysts anticipate that Xenon Pharmaceuticals Inc. will post ($0.96) earnings per share for the current year.
A number of analysts recently commented on XENE shares. Jefferies Group LLC dropped their price target on shares of Xenon Pharmaceuticals from $8.00 to $5.00 and set a “buy” rating on the stock in a research note on Wednesday, June 28th. Canaccord Genuity restated a “buy” rating and set a $5.00 price target on shares of Xenon Pharmaceuticals in a research note on Tuesday, June 27th. Finally, Zacks Investment Research upgraded shares of Xenon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, July 1st. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $11.88.
Institutional investors have recently bought and sold shares of the company. KCG Holdings Inc. purchased a new position in Xenon Pharmaceuticals during the first quarter worth $122,000. Scotia Capital Inc. raised its position in Xenon Pharmaceuticals by 36.0% in the second quarter. Scotia Capital Inc. now owns 35,629 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 9,426 shares during the last quarter. Renaissance Technologies LLC raised its position in Xenon Pharmaceuticals by 18.7% in the fourth quarter. Renaissance Technologies LLC now owns 114,200 shares of the biopharmaceutical company’s stock worth $879,000 after buying an additional 18,000 shares during the last quarter. K2 Principal Fund L.P. raised its position in Xenon Pharmaceuticals by 104.4% in the first quarter. K2 Principal Fund L.P. now owns 116,975 shares of the biopharmaceutical company’s stock worth $468,000 after buying an additional 59,747 shares during the last quarter. Finally, Sabby Management LLC purchased a new position in Xenon Pharmaceuticals during the first quarter worth $1,186,000. Institutional investors and hedge funds own 56.01% of the company’s stock.
Xenon Pharmaceuticals Company Profile
Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD).
Receive News & Stock Ratings for Xenon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.